DEF: Jupiter Neurosciences Seeks Shareholder Approval for Major Capital Raise

Jupiter Neurosciences, Inc. is seeking stockholder approval for a significant increase in authorized common stock and a $20 million equity purchase agreement to fund its operations and clinical trials.

Summary

• An Annual Meeting will be held virtually on December 19, 2025, at 10:00 a.m. Eastern Time, for stockholders of record as of October 24, 2025.
• Stockholders will vote on six proposals, including the election of seven directors, an increase in authorized common stock, adoption of a new equity incentive plan, ratification of auditors, and approval of a standby equity purchase agreement.
• The company proposes to amend its certificate of incorporation to increase the authorized shares of common stock from 125,000,000 to 500,000,000 shares, representing a 300% increase.
• Approval is sought for the Jupiter Neurosciences, Inc. 2025 Equity Incentive Plan, which would make 5,250,000 shares available for awards, replacing the 2023 Plan that has 1,047,135 shares remaining.
• The company entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD (Yorkville) to sell up to $20.0 million of its common stock, at the company's option, at a price equal to 97% of the lowest daily VWAP during a three-day pricing period.
• A pre-paid advance of $6.0 million from Yorkville is structured through two convertible promissory notes: a $4.0 million note (7.0% OID) already disbursed for $3,720,000, and a $2.0 million note (7.0% OID) for $1,860,000 to be disbursed upon regulatory and stockholder approvals.
• These convertible notes have an initial conversion price of $1.50 per share, subject to price protection antidilution adjustments that could reduce the conversion price to an absolute floor of $0.296 per share.
• Proceeds from the SEPA are intended to fund the Phase 2 trial of JOTROL for Parkinson's Disease, accelerate direct-to-consumer marketing and sales growth for the Nugevia.com product line, and for general working capital.
• Executive salaries were deferred and reduced in 2023, and accrued compensation totaling $4,189,626 and bonuses of $583,213 were forgiven in exchange for equity in 2023.

Sentiment

Score: 3

Explanation: While the company has secured a significant capital raise, the terms involve substantial potential dilution for existing shareholders due to the large increase in authorized shares, the nature of the SEPA pricing, and the low floor price on convertible notes. This indicates ongoing financial challenges and a reliance on dilutive financing, outweighing the positive of securing funds for clinical trials and product launch.

Positives

• Secured a Standby Equity Purchase Agreement (SEPA) with Yorkville for up to $20.0 million, providing a potential source of capital for future operations.
• Received an initial $3,720,000 pre-paid advance from Yorkville, with another $1,860,000 expected upon necessary approvals, injecting immediate and near-term capital.
• The capital is earmarked for critical initiatives: funding the Phase 2 clinical trial of JOTROL for Parkinson's Disease and accelerating direct-to-consumer marketing for the Nugevia.com product line, which could drive future growth.
• Established a new Compensation Recovery Policy (Clawback Policy) on March 26, 2025, in compliance with SEC and Nasdaq rules, enhancing corporate governance and accountability.
• Maintains a majority independent board of directors (4 out of 7), with all key committees (Audit, Compensation, Nominating & Corporate Governance) chaired and composed of independent directors, promoting strong oversight.
• The company benefits from an active Scientific Advisory Board and business advisors, enabling effective execution of multiple pipeline projects with a relatively small staff.

Negatives

• Proposing a substantial increase in authorized common stock from 125,000,000 to 500,000,000 shares (a 300% increase), which will result in significant dilution for existing stockholders upon issuance.
• The Standby Equity Purchase Agreement (SEPA) with Yorkville involves potential issuance of shares at 97% of the lowest daily VWAP during a three-day pricing period, which is inherently dilutive and could be significantly below current market prices.
• Convertible promissory notes issued to Yorkville have a fixed conversion price of $1.50 per share but are subject to price protection antidilution adjustments, potentially reducing the conversion price to an absolute floor of $0.296. This could lead to extreme dilution; for example, a $4.0 million note could convert into 13,513,514 shares at $0.296, compared to 2,666,667 shares at $1.50.
• Executive salaries were deferred and reduced in 2023, and accrued compensation and bonuses were forgiven in exchange for equity, indicating past and potentially ongoing cash flow challenges and a reliance on dilutive financing.
• The SEPA restricts repayment of loans to executives/employees and related party debt until the convertible notes are fully repaid, with limited exceptions for bonuses, which could impact internal financial flexibility.
• A finder's fee of 8.0% of pre-paid advance proceeds and $18,000 per month for 12 months (total $216,000) is payable to Revere Securities LLC, adding to the cost of capital raising.

Risks

• **Dilution**: Future issuance of additional shares of Common Stock from the proposed increase in authorized shares and the SEPA would dilute the voting rights, earnings per share, and book value per share of existing stockholders.
• **Market Price Decline**: The sale or resale of shares issued under the SEPA and upon conversion of convertible notes could cause prevailing market prices for the Common Stock to decline.
• **Financing Dependence**: Failure to approve Proposal No. 5 (SEPA share issuance) would prevent the company from selling shares to Yorkville in excess of the Nasdaq Exchange Cap at prices below the Minimum Price, potentially impairing working capital and the ability to fund operations.
• **Convertible Note Price Protection**: The conversion price of the convertible notes is subject to price protection antidilution adjustments, which could significantly increase the number of shares issued to Yorkville if the stock price declines, leading to greater dilution.
• **Related Party Debt Restrictions**: The SEPA restricts repayment of loans to executives/employees and related party debt until the convertible notes are fully repaid, which could impact internal financial flexibility.
• **Virtual Meeting Format**: While designed for participation, virtual meetings can sometimes present technical challenges or reduce the perceived direct engagement compared to in-person meetings.

Future Outlook

The company plans to utilize proceeds from the Standby Equity Purchase Agreement to fund its Phase 2 clinical trial for JOTROL, targeting Parkinson's Disease, and to accelerate direct-to-consumer marketing and sales growth for its Nugevia.com nutritional product line. The capital will also support general working capital and other corporate purposes.

Management Comments

• "We have designed the format of the Annual Meeting to ensure that you are afforded the same rights and opportunities to participate as you would at an in-person meeting, using online tools to ensure your access and participation." (Christer Rosn, Chairman and CEO)
• "On behalf of the Board of Directors, thank you for your continued confidence and investment in Jupiter." (Christer Rosn, Chairman and CEO)
• "We believe that combining the positions of Chairman and Chief Executive Officer allows for focused leadership of our organization which benefits us in our relationships with investors, customers, suppliers, employees and other constituencies." (Board of Directors)
• "We believe the proceeds that we expect to receive pursuant to the SEPA, and the proceeds we did and will receive from the issuance of the Convertible Notes will allow us to fund our business operations." (Board of Directors)
• "We expect that the SEPA will provide us with future flexibility to enhance our liquidity in an opportunistic and efficient manner, and only when we deem it to be necessary." (Board of Directors)
• "We remain focused on creating long-term value for our stockholders, and the SEPA will allow us to be strategic in how we access and deploy capital to continue normal business operations." (Board of Directors)

Industry Context

Jupiter Neurosciences operates in the biotechnology and pharmaceutical sectors, focusing on neurological disorders (e.g., Parkinson's Disease with JOTROL) and nutritional products (Nugevia.com). The need for significant capital raises, often through dilutive equity financing, is common for early to mid-stage biotech companies to fund expensive clinical trials and product development, especially given the long development cycles and high R&D costs in the industry. The dual focus on pharmaceuticals and nutritional products suggests a strategy to diversify revenue streams while pursuing high-risk, high-reward drug development.

Comparison to Industry Standards

• The capital raise structure, involving a Standby Equity Purchase Agreement (SEPA) and convertible notes with price protection, is a common, albeit often dilutive, financing mechanism for smaller public companies in the biotech sector that may have limited access to traditional equity markets.
• The proposed increase in authorized shares to 500 million from 125 million is a substantial increase, which is not uncommon for growth-oriented biotech companies anticipating future capital needs, but it is on the higher end and signals significant potential future dilution.
• The 2025 Equity Incentive Plan, reserving 5.25 million shares, is a standard practice to attract and retain talent in the competitive life sciences industry, comparable to plans at similar-sized biotech firms.
• The company's strategy to fund a Phase 2 trial (JOTROL for Parkinson's) and accelerate direct-to-consumer marketing for a nutritional product (Nugevia.com) reflects a common dual-track approach in the industry: pursuing high-value drug development while generating nearer-term revenue from less regulated products.

Corporate Governance

Related Party Transactions

• Christer Rosn (Chairman and CEO) has loaned the company working capital since inception, with a balance of $146,432 as of June 30, 2025, accruing 3% interest per year.
• An employee loaned the company $25,000 in 2023, which was repaid in 2024.
• On April 29, 2024, the CEO exchanged 685,869 shares for related party notes totaling $266,667, and the note maturity was extended to August 11, 2024, designated as a 10% original issue discount secured note.
• Accrued compensation to executives has been partially paid, deferred, and reduced, indicating cash flow management.
• On September 29, 2023, employees and board members forgave $4,189,626 in accrued compensation in exchange for 2,353,661 stock options and 1,399,834 restricted stock units.
• On December 18, 2023, cash bonuses of $513,013 for employees and $70,200 for board members were forgiven in exchange for additional equity (289,294 stock options and 218,703 restricted stock units).
• Saleem Elmasri (CFO) provides services through Titan Advisory Services LLC, a company wholly-owned by him and his wife. The monthly fee for these services was reduced from $25,000 to $5,000 in 2023, then set at $20,000 for 2025.
• Allison W. Brady, an independent director, is a co-founder of Gene Spotlight, Inc., which is currently the largest outside investor in the company.

Stakeholder Impact

• **Shareholders**: Face significant potential dilution from the proposed increase in authorized shares and the Standby Equity Purchase Agreement (SEPA) with Yorkville, particularly due to the variable pricing and low floor price on convertible notes. Their voting power and per-share value could decrease.
• **Employees/Executives**: Experienced salary deferrals and reductions in 2023, with accrued compensation and bonuses converted into equity, indicating financial sacrifices. The new equity incentive plan aims to attract and retain talent. Repayment of related party debt (including executive loans/salaries) is restricted by the SEPA until convertible notes are fully repaid, potentially impacting executive liquidity.
• **Creditors (Yorkville)**: Will receive convertible notes with an 8% interest rate and potential for 18% upon default, along with commitment shares and favorable conversion terms, providing them with a strong position.
• **Customers**: Potential for new product development (JOTROL for Parkinson's) and accelerated marketing of existing products (Nugevia.com) could benefit customers by offering new or more accessible solutions.

Next Steps

• Hold the 2025 virtual Annual Meeting of Stockholders on December 19, 2025.
• File a registration statement with the SEC for the resale of shares issuable under the SEPA within 30 calendar days of October 24, 2025.
• Disburse the second tranche of the Pre-Paid Advance ($1,860,000) after the initial Registration Statement becomes effective and requisite stockholder approval for excess of Exchange Cap is obtained.
• If approved, file the amendment to the certificate of incorporation promptly after the Annual Meeting to increase authorized shares.
• Continue funding the Phase 2 trial of JOTROL for Parkinson's Disease.
• Accelerate direct-to-consumer marketing and sales growth of Nugevia.com.
• File a Current Report on Form 8-K with the SEC within four business days after the Annual Meeting to disclose final voting results.

Key Dates

Recommendation

The company is seeking approval for a 300% increase in authorized common stock and a $20 million dilutive equity financing agreement (SEPA) with Yorkville, which includes convertible notes with a potential conversion price as low as $0.296 per share. This level of potential dilution, coupled with past executive salary deferrals and compensation forgiveness, signals significant financial distress and a high risk to existing shareholder value. While the capital is needed for clinical trials and product launch, the terms are highly unfavorable, suggesting a 'sell' recommendation for current investors to mitigate further losses from dilution.

Keywords

Jupiter Neurosciences, SEC Filing, Proxy Statement, DEF 14A, Stockholder Meeting, Equity Incentive Plan, Authorized Shares Increase, Standby Equity Purchase Agreement, SEPA, Convertible Notes, Capital Raise, Dilution, Corporate Governance, Executive Compensation, JOTROL, Parkinson's Disease, Nugevia.com, Biotechnology, Pharmaceuticals, Nasdaq Listing Rules